

# Site Metrics for Study Start-Up Project Overview


May 4, 2011



# Project Goal

**To identify core data elements that should be collected by all clinical trial sites to allow measurement and improvement of important timeframes for study start-up**

# Project Organization



Project approved by CTTI Executive Committee 24-Sept-2010

Received authoritative determination from the Duke IRB that this research does not qualify as *human subjects research* on 25-October 2010

# Workstream 1: Retrospective Data Collection

## Objective

To complete an analysis of the current state of study start-up at sites participating in multicenter clinical trials, including the range of variability in performance using cycle time metrics and a variety of stratifications

# Data Collection

- Invitations to participate sent 3-Nov -2010
- Data received from 18 organizations representing:
  - Academic
  - CRO-ARO
  - Biotechnology
  - Device
  - Government
  - Investigators
  - Pharmaceutical
- Data submitted for a 12 month consecutive period
- Results will be reported in the next presentation

# Workstream 2 – Expert Meeting May 4, 2011

## Objective

- **Through expert meeting with key stakeholders**
  - ◆ **Define appropriate site start up metrics to be prospectively collected and analyzed**
  - ◆ **Include a standard, specific and measureable definition for each metric**
  - ◆ **Agree on set of metrics for inclusion in prospective data collection pilot**

**Proposed metrics for today's discussion was developed by a working group in collaboration with CTTI staff**

# WS-2 Working Group Representation

<b>Academic Institutions</b> <ul style="list-style-type: none"><li>- Duke University</li><li>- UCSF</li><li>- University of Michigan</li></ul>	<b>Rob Califf, Swati Chakraborty Clay Johnston Dan Ford</b>
<b>Pharmaceutical Companies</b> <ul style="list-style-type: none"><li>- Pfizer</li></ul>	<b>Briggs Morrison, Soo Bang</b>
<b>US Government</b> <ul style="list-style-type: none"><li>- FDA</li><li>- NIH</li></ul>	<b>Barabara Buch, Jonathan Helfgott, Susan Libenhaut Andrea Denicoff, Jonathan Kagan</b>
<b>CROs</b> <ul style="list-style-type: none"><li>- ICON</li><li>- Quintiles</li></ul>	<b>Julian Rimmer Amy Kissam, Debbie Liske</b>
<b>Biotechnology Companies</b> <ul style="list-style-type: none"><li>- Amgen</li></ul>	<b>Brian York</b>
<b>Device/Diagnostics Companies</b> <ul style="list-style-type: none"><li>- J&amp;J Device</li></ul>	<b>Lori Lonzetta</b>
<b>Clinical Investigator Groups)</b> <ul style="list-style-type: none"><li>- RX Trials, Inc.</li></ul>	<b>Christine Pierre</b>
<b>Standard Setting Organizations</b> <ul style="list-style-type: none"><li>- CDISC</li></ul>	<b>Becky Kush</b>



# Workstream 3 Prospective Data Collection

- **Prospective data collection pilot**
  - ◆ **Focus is on sites reporting their own data**
  - ◆ **Output from today's meeting will help inform the planning and implementation of Workstream 3**
    - ◆ **Metrics to be collected**
    - ◆ **Strategies for success & potential barriers**
    - ◆ **Recommended requirements for an electronic data collection tool for use by sites for reporting requested data**
    - ◆ **Site identification and recruitment**
  - ◆ **Timeline**
    - ◆ **Initiation of data collected targeted for Sept 2011**
    - ◆ **Duration and scope of pilot TBD**



QUESTIONS??